Trials / Terminated
TerminatedNCT04975399
Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma
A Phase 1, Multi-center, Open-label, Dose Finding Study of CC-92328 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This Phase 1, first-in-human (FIH), clinical study of CC-92328 will explore the safety, tolerability and preliminary biological and clinical activity of CC-92328 as a single-agent in the setting of relapsed and/or refractory multiple myeloma (R/R MM). The study will be conducted in two parts: monotherapy dose escalation (Part A) and monotherapy dose expansion (Part B).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CC-92328 | CC-92328 |
Timeline
- Start date
- 2021-10-05
- Primary completion
- 2024-06-18
- Completion
- 2024-06-18
- First posted
- 2021-07-23
- Last updated
- 2025-03-24
Locations
15 sites across 3 countries: United States, Canada, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04975399. Inclusion in this directory is not an endorsement.